These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 22320343)

  • 21. Identification of new aminoacid amides containing the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling.
    Furlan A; Colombo F; Kover A; Issaly N; Tintori C; Angeli L; Leroux V; Letard S; Amat M; Asses Y; Maigret B; Dubreuil P; Botta M; Dono R; Bosch J; Piccolo O; Passarella D; Maina F
    Eur J Med Chem; 2012 Jan; 47(1):239-54. PubMed ID: 22138308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
    Pan BS; Chan GK; Chenard M; Chi A; Davis LJ; Deshmukh SV; Gibbs JB; Gil S; Hang G; Hatch H; Jewell JP; Kariv I; Katz JD; Kunii K; Lu W; Lutterbach BA; Paweletz CP; Qu X; Reilly JF; Szewczak AA; Zeng Q; Kohl NE; Dinsmore CJ
    Cancer Res; 2010 Feb; 70(4):1524-33. PubMed ID: 20145145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel potent orally active multitargeted receptor tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of 2-indolinone derivatives.
    Cho TP; Dong SY; Jun F; Hong FJ; Liang YJ; Lu X; Hua PJ; Li LY; Lei Z; Bing H; Ying Z; Qiong LF; Bei FB; Guang LL; Shen GA; Hong SG; Hong SW; Tai MX
    J Med Chem; 2010 Nov; 53(22):8140-9. PubMed ID: 21028894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands.
    Asses Y; Leroux V; Tairi-Kellou S; Dono R; Maina F; Maigret B
    Chem Biol Drug Des; 2009 Dec; 74(6):560-70. PubMed ID: 19909299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458).
    Liu L; Siegmund A; Xi N; Kaplan-Lefko P; Rex K; Chen A; Lin J; Moriguchi J; Berry L; Huang L; Teffera Y; Yang Y; Zhang Y; Bellon SF; Lee M; Shimanovich R; Bak A; Dominguez C; Norman MH; Harmange JC; Dussault I; Kim TS
    J Med Chem; 2008 Jul; 51(13):3688-91. PubMed ID: 18553959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model.
    Kim SJ; Johnson M; Koterba K; Herynk MH; Uehara H; Gallick GE
    Clin Cancer Res; 2003 Nov; 9(14):5161-70. PubMed ID: 14613995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group.
    Milkiewicz KL; Aimone LD; Albom MS; Angeles TS; Chang H; Grobelny JV; Husten J; Losardo C; Miknyoczki S; Murthy S; Rolon-Steele D; Underiner TL; Weinberg LR; Worrell CS; Zeigler KS; Dorsey BD
    Bioorg Med Chem; 2011 Nov; 19(21):6274-84. PubMed ID: 21967808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.
    Gingrich DE; Reddy DR; Iqbal MA; Singh J; Aimone LD; Angeles TS; Albom M; Yang S; Ator MA; Meyer SL; Robinson C; Ruggeri BA; Dionne CA; Vaught JL; Mallamo JP; Hudkins RL
    J Med Chem; 2003 Dec; 46(25):5375-88. PubMed ID: 14640546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pyrazolone-based anaplastic lymphoma kinase (ALK) inhibitors: control of selectivity by a benzyloxy group.
    Tripathy R; McHugh RJ; Ghose AK; Ott GR; Angeles TS; Albom MS; Huang Z; Aimone LD; Cheng M; Dorsey BD
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7261-4. PubMed ID: 22061645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, and evaluation of a novel dual FMS-like tyrosine kinase 3/stem cell factor receptor (FLT3/c-KIT) inhibitor for the treatment of acute myelogenous leukemia.
    Davies RJ; Pierce AC; Forster C; Grey R; Xu J; Arnost M; Choquette D; Galullo V; Tian SK; Henkel G; Chen G; Heidary DK; Ma J; Stuver-Moody C; Namchuk M
    J Med Chem; 2011 Oct; 54(20):7184-92. PubMed ID: 21970471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).
    Cui JJ; Tran-Dubé M; Shen H; Nambu M; Kung PP; Pairish M; Jia L; Meng J; Funk L; Botrous I; McTigue M; Grodsky N; Ryan K; Padrique E; Alton G; Timofeevski S; Yamazaki S; Li Q; Zou H; Christensen J; Mroczkowski B; Bender S; Kania RS; Edwards MP
    J Med Chem; 2011 Sep; 54(18):6342-63. PubMed ID: 21812414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovering potent inhibitors against c-Met kinase: molecular design, organic synthesis and bioassay.
    Liang Z; Ding X; Ai J; Kong X; Chen L; Chen L; Luo C; Geng M; Liu H; Chen K; Jiang H
    Org Biomol Chem; 2012 Jan; 10(2):421-30. PubMed ID: 22108637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and structure-activity relationship of aminopyridines with substituted benzoxazoles as c-Met kinase inhibitors.
    Lee J; Han SY; Jung H; Yang J; Choi JW; Chae CH; Park CH; Choi SU; Lee K; Ha JD; Lee CO; Ryu JW; Kim HR; Koh JS; Cho SY
    Bioorg Med Chem Lett; 2012 Jun; 22(12):4044-8. PubMed ID: 22579487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells.
    Wang SY; Chen B; Zhan YQ; Xu WX; Li CY; Yang RF; Zheng H; Yue PB; Larsen SH; Sun HB; Yang X
    J Hepatol; 2004 Aug; 41(2):267-73. PubMed ID: 15288476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
    Christensen JG; Burrows J; Salgia R
    Cancer Lett; 2005 Jul; 225(1):1-26. PubMed ID: 15922853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pyrazolone based TGFbetaR1 kinase inhibitors.
    Guckian K; Carter MB; Lin EY; Choi M; Sun L; Boriack-Sjodin PA; Chuaqui C; Lane B; Cheung K; Ling L; Lee WC
    Bioorg Med Chem Lett; 2010 Jan; 20(1):326-9. PubMed ID: 19914068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of 4-azaindoles as novel inhibitors of c-Met kinase.
    Porter J; Lumb S; Franklin RJ; Gascon-Simorte JM; Calmiano M; Riche KL; Lallemand B; Keyaerts J; Edwards H; Maloney A; Delgado J; King L; Foley A; Lecomte F; Reuberson J; Meier C; Batchelor M
    Bioorg Med Chem Lett; 2009 May; 19(10):2780-4. PubMed ID: 19369077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis and molecular docking studies of some novel spiro[indoline-3, 4'-piperidine]-2-ones as potential c-Met inhibitors.
    Ye L; Tian Y; Li Z; Jin H; Zhu Z; Wan S; Zhang J; Yu P; Zhang J; Wu S
    Eur J Med Chem; 2012 Apr; 50():370-5. PubMed ID: 22381355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.